Ventures

Respiosa offers a groundbreaking solution for obstructive sleep apnea (OSA), a condition affecting millions worldwide. Unlike traditional treatments like CPAP or surgery, Respiosa provides a minimally invasive, surgically implanted solution specifically targeting tongue-based obstruction, a common cause of OSA. Developed by Philips, Respiosa promises effective, durable, and adjustable therapy with a quick recovery time. With its natural and unobtrusive design, Respiosa ensures high patient adherence, addressing a significant gap in OSA treatment options.

Nilocas offers a revolutionary solution for detecting coronary artery disease non-invasively and without radiation. Patients wear a lightweight chest patch that captures the sounds of turbulent blood flow through arteries using microphones and accelerometers. Advanced machine learning and AI rapidly analyze the data, providing a clear diagnosis in just 10 minutes. This innovation eliminates the need for costly and invasive procedures, making cardiac diagnosis more accessible in both clinical and non-clinical settings.

Axial Orthopaedics Inc. revolutionizes trauma treatment with their innovative intramedullary nailing system. Current systems often lead to bone misalignment and joint pain, blocking post-procedural recovery. Axial Orthopaedics's modular system offers greater flexibility in bone alignment and healing. This system not only addresses postoperative pain but also reduces complications. Its intra-operative modularity and rotational capabilities allow surgeons to achieve better fracture fixation and improved outcomes, filling a crucial gap in current technology.

NLC's venture, Profionics, advances Cardiff University's sepsis research with a biomarker test combining AI, gene expression, and metabolic analysis for rapid, accurate diagnosis. This test, which works in under 30 minutes with a drop of blood, surpasses traditional methods by quickly identifying those needing antibiotics and reducing unnecessary use, thus combating antimicrobial resistance and saving lives. Particularly impactful in neonatal care, it ensures timely detection critical for newborn survival. Founded by NLC, Cardiff University, and CEO Darren Fergus, Profionics leverages extensive research and a blood sample BioBank, positioning itself as a leader in host response diagnostic testing.

AGO have developed a handy tool called the Aortic Root Pressurizing Device (ARPD) to help during heart surgeries. This device allows surgeons to check the success of aortic valve repairs while the heart is temporarily stopped. It helps avoid the need to restart the heart to check, which can be risky and time-consuming. The ARPD makes surgeries safer, quicker, and cheaper by allowing surgeons to verify their work during the operation. It's easy to use and disposable, so it doesn't add much hassle to the surgery process.

Laparoscopic surgery, while effective, faces limitations in low-resource areas due to cost and sustainability concerns associated with CO2 insufflation. Gasless laparoscopy provides an alternative, that are costly and difficult to use. To address these challenges, LORESA has developed an affordable and user-friendly gasless laparoscopy retractor, designed with input from surgeons worldwide, offering improved usability and cost-effectiveness. This innovation, aims to democratize laparoscopic techniques, benefiting rural hospitals and developing communities.

Scinvivo introduces a solution for bladder cancer diagnosis with its imaging catheter, providing real-time, cross-sectional tissue images. Traditional methods often lead to unnecessary surgeries and missed tumors. By utilizing Optical Coherence Tomography technology, Scinvivo's catheter offers high-resolution imaging, enabling urologists to accurately diagnose bladder conditions. This approach reduces unnecessary surgeries but also enhances diagnostic accuracy, improving patient outcomes.

Foveo Fertility addresses the challenge of improving in vitro fertilization (IVF) success rates by providing a stable physiological environment for egg cells. Unlike current methods that expose egg cells to air, leading to cooling and evaporation, Foveo Fertility ensures consistent conditions for optimal egg cell quality. This innovation also streamlines workflow in the IVF lab, reducing human error and saving time for embryologists. With no other product on the market offering constant physiological conditions for egg cells, Foveo Fertility aims to improve the lives of both lab workers and patients by maximizing the potential for successful pregnancies.